* Cyclo Therapeutics Inc reported a quarterly adjusted loss of 27 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -29 cents. The mean expectation of three analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -19 cents to -13 cents per share.

* Revenue fell 53% to $233.00 thousand from a year ago; analysts expected $294.00 thousand.

* Cyclo Therapeutics Inc's reported EPS for the quarter was a loss of 31 cents​.

* The company reported a quarterly loss of $8.83 million.

* Cyclo Therapeutics Inc shares had fallen by 8.7% this quarter and lost 54.7% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 5% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Cyclo Therapeutics Inc is $0.95 This summary was machine generated from LSEG data November 14 at 08:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.16 -0.27 Missed

Jun. 30 2024 -0.15 -0.21 Missed

Mar. 31 2024 -0.20 -0.15 Beat

-0.34